| pubmed-article:9873499 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9873499 | lifeskim:mentions | umls-concept:C0038661 | lld:lifeskim |
| pubmed-article:9873499 | lifeskim:mentions | umls-concept:C0031667 | lld:lifeskim |
| pubmed-article:9873499 | lifeskim:mentions | umls-concept:C0038477 | lld:lifeskim |
| pubmed-article:9873499 | lifeskim:mentions | umls-concept:C0243077 | lld:lifeskim |
| pubmed-article:9873499 | lifeskim:mentions | umls-concept:C0205549 | lld:lifeskim |
| pubmed-article:9873499 | pubmed:issue | 16 | lld:pubmed |
| pubmed-article:9873499 | pubmed:dateCreated | 1999-1-28 | lld:pubmed |
| pubmed-article:9873499 | pubmed:abstractText | A series of mechanism-based inhibitors of phospholipase A2 (SIBLINKS) were synthesized. These new SIBLINKS are phospholipid analogues that contain a para-substituted phenyl 3,3-dimethylglutaryl group in the place of the sn-2 acyl chain. The effect of the phenyl leaving group on inhibitory activity was studied by varying the electron-withdrawing ability of the para-substituted group. A strong correlation was observed between the leaving group potential of the suicide inhibitor and the inhibitory activity of the derivative toward cobra venom phospholipase A2. | lld:pubmed |
| pubmed-article:9873499 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9873499 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9873499 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9873499 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9873499 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9873499 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9873499 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9873499 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9873499 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9873499 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9873499 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:9873499 | pubmed:issn | 0960-894X | lld:pubmed |
| pubmed-article:9873499 | pubmed:author | pubmed-author:CouttsS MSM | lld:pubmed |
| pubmed-article:9873499 | pubmed:author | pubmed-author:VictoriaE JEJ | lld:pubmed |
| pubmed-article:9873499 | pubmed:author | pubmed-author:ChangJJ | lld:pubmed |
| pubmed-article:9873499 | pubmed:author | pubmed-author:YuLL | lld:pubmed |
| pubmed-article:9873499 | pubmed:author | pubmed-author:TernanskyR... | lld:pubmed |
| pubmed-article:9873499 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9873499 | pubmed:day | 18 | lld:pubmed |
| pubmed-article:9873499 | pubmed:volume | 8 | lld:pubmed |
| pubmed-article:9873499 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9873499 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9873499 | pubmed:pagination | 2129-32 | lld:pubmed |
| pubmed-article:9873499 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:9873499 | pubmed:meshHeading | pubmed-meshheading:9873499-... | lld:pubmed |
| pubmed-article:9873499 | pubmed:meshHeading | pubmed-meshheading:9873499-... | lld:pubmed |
| pubmed-article:9873499 | pubmed:meshHeading | pubmed-meshheading:9873499-... | lld:pubmed |
| pubmed-article:9873499 | pubmed:meshHeading | pubmed-meshheading:9873499-... | lld:pubmed |
| pubmed-article:9873499 | pubmed:meshHeading | pubmed-meshheading:9873499-... | lld:pubmed |
| pubmed-article:9873499 | pubmed:meshHeading | pubmed-meshheading:9873499-... | lld:pubmed |
| pubmed-article:9873499 | pubmed:meshHeading | pubmed-meshheading:9873499-... | lld:pubmed |
| pubmed-article:9873499 | pubmed:meshHeading | pubmed-meshheading:9873499-... | lld:pubmed |
| pubmed-article:9873499 | pubmed:meshHeading | pubmed-meshheading:9873499-... | lld:pubmed |
| pubmed-article:9873499 | pubmed:meshHeading | pubmed-meshheading:9873499-... | lld:pubmed |
| pubmed-article:9873499 | pubmed:meshHeading | pubmed-meshheading:9873499-... | lld:pubmed |
| pubmed-article:9873499 | pubmed:meshHeading | pubmed-meshheading:9873499-... | lld:pubmed |
| pubmed-article:9873499 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9873499 | pubmed:articleTitle | The structure-activity relationships of a series of suicide inhibitors of phospholipase A2. | lld:pubmed |
| pubmed-article:9873499 | pubmed:affiliation | La Jolla Pharmaceutical Co., San Diego, CA 92121, USA. | lld:pubmed |
| pubmed-article:9873499 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:9873499 | lld:chembl |
